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ICH guidelineAbstract A rapid and precise method (in accordance with ICH guidelines) is developed for the
quantitative simultaneous determination of Drotaverine hydrochloride and Omeprazole in a com-
bined pharmaceutical dosage form. Three methods are described for the simultaneous determina-
tion of Drotaverine hydrochloride and Omeprazole in a binary mixture. The ﬁrst method was
based on UV-Spectrophotometric determination of two drugs, using Vierordt!s simultaneous equa-
tion method. It involves absorbance measurement at 226.8 nm (kmax of Drotaverine hydrochloride)
and 269.4 nm (kmax of Omeprazole) in methanol; linearity was obtained in the range of 5–
30 lg ml1 for both the drugs. The second method was based on HPLC separation of the two drugs
using potassium dihydrogen phosphate buffer pH 5.0: Acetonitrile: Triethylamine (60:40:0.5, v/v) as
a mobile phase. Areas were recorded at 260 nm for both the drugs and retention time was found to
be 2.71 min. and 3.87 min for Drotaverine hydrochloride and Omeprazole, respectively at 1.0 mL/
min ﬂow rate. The selected chromatographic conditions were found to determine Drotaverine
hydrochloride and Omeprazole quantitatively in a combined dosage form without any physical sep-
aration. The method has been validated for linearity, accuracy and precision. Linearity was found
over the range of 5–30 lg mL1 for both drugs. The third method was based on HPTLC method for
simultaneous quantiﬁcation of these compounds in pharmaceutical dosage forms. Precoated silica
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Figure 1 Structure of Drota
S398 S. Sharma, M.C. Sharmagel 60 F254 plate was used as stationary phase. The separation was carried out using Glacial acetic
acid:Cyclohexane:Methanol:(80:15:5 v/v/v) as mobile phase. The proposed method was found to be
fast, accurate, precise, reproducible and rugged and can be used for a simultaneous analysis of these
drugs in combined formulations.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).O
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Figure 2 Structure of Omeprazole.1. Introduction
Drotaverine hydrochloride (DRO) chemically 1-[(3,4-[dieth-
oxyphenyl) methylene]-6,7-diethoxy-1,2,3,4-tetrahydroisoqui-
nolene (Fig. 1) is a papaverine analog mainly used as an
antispasmodic and smooth-muscle relaxant in pain associated
with gastrointestinal colic, biliary colic, and postsurgical
spasms. It is an antispasmodic agent with smooth muscle
relaxant properties. It exerts its action by inhibiting phospho-
diesterase enzyme IV which is speciﬁc for smooth muscles
(Sweetman, 2002; Oneil et al., 2001). Omeprazole (Fig. 2) is
chemically known as 6-methoxy-2-[(4-methoxy-3,5-dimethyl-
pyridin-2-yl)methylsulﬁnyl]-1H-benzimidazole. Omeprazole is
a used as an antiulcer drug and against other acid-related dis-
eases (Stenhoff et al., 1999). Omeprazole (OME) is the proton
pump inhibitor. In the acidic conditions of the stomach, Ome-
prazole reacts with a cysteine group in H+/K+-ATPase,
thereby destroying the ability of the parietal cells to produce
gastric acid (Tripathi, 2008). Literature review reveals that
methods have been reported for the analysis of Drotaverine
hydrochloride by high-performance liquid chromatography
(Bolaji et al., 1993; Lalla et al., 1993; Metwally et al., 2006;
Panigrahi and Sharma, 2008; Patel et al., 2007; Topagi et al.,
2010; Metwally, 2008), thin layer chromatography (Ayad
et al., 2006; Metwally et al., 2006), spectrophotometry (Abdel-
latef et al., 2007; Dahivelkar et al., 2007; Kothapalli et al.,
2010) and voltammetry (Ziyatdinova et al., 2007). Several ana-
lytical methods that have been reported for an estimation of
Omeprazole are HPLC (Dubuc et al., 2001; El-Sherif et al.,
2006; Murakami et al., 2007; Subramanian and Kumar,2007),
LC–MS (Petsalo et al., 2008) and HPTLC (Raval et al., 2008).
For Omeprazole methods reported are HPLC–MS and
HPLC–UV in biological ﬂuids (Kange et al., 2006; Yuch
et al., 2001), capillary electrophoresis (Berzas and Castanda,
2005), HPLC employing electrochemical and coulometricNH
.HCl
verine hydrochloride.detection (Gregory et al., 2001), TLC (Agbaba et al., 2004)
and spectrophotometry (Lakshmi and Venkatesan, 2003).
The purpose of this research was to establish and validate,
in accordance with International Conference on Harmoniza-
tion (ICH) guidelines, an accurate, economical, and reproduc-
ible procedure for quantitative analysis of Drotaverine
hydrochloride and Omeprazole as the bulk drug and in tablet
dosage forms. It was thought worthwhile to develop precise,
accurate UV spectrophotometric, HPLC and HPTLC methods
for simultaneous determination of Drotaverine hydrochloride
and Omeprazole in tablets.
2. Materials and methods
2.1. Chemicals and reagents
Commercially available Ranispas-DV (Penta Biotech, India)
drug containing 40 mg of Drotaverine hydrochloride and
10 mg of Omeprazole was used. HPLC grade acetonitrile and
AR grade potassium dihydrogen phosphate was purchased
from Merck, India and were used as received. All other re-
agents employed are of high purity analytical grade.
2.2. UV-spectrophotometry
SHIMADZU double beam UV/Visible recording spectropho-
tometer (Model:1700) with 2 nm spectral bandwidth was em-
ployed for all spectrophotometric measurements using
10 mm matched quartz cell and Borosil glass wares were used
for the study. Calibrated electronic single pan balances Sarto-
rius CP 225 D, pH Meter, Enertech Fast Clean Ultrasonicator
were also used during the analysis. UV-Spectrophotometric
determination of two drugs was done using Vierordt!s simulta-
neous equation method (Davidson et al., 2001).
2.2.1. Standard stock solution
The standard stock solutions of Drotaverine hydrochloride
and Omeprazole were prepared by dissolving accurately
weighed 100 mg of drug in 100 ml of a mixture of methanol
and double distilled water (50:50) in two separate 100 ml vol-
umetric ﬂasks to get a concentration of 1000 lg/ml. Both were
appropriately diluted with a mixture of methanol and double
distilled water (50:50) to get a concentration of 100 lg/ml
and were kept as stock solutions.
Figure 3 Overlain spectra of theDrotaverineHCl andOmeprazole.
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The standard solution of both Drotaverine hydrochloride and
Omeprazole (10 lg/ml) were scanned in the wavelength region
of 200–400 nm and the kmax was found to be 226.8 nm (kmax of
Drotaverine hydrochloride) and 269.4 nm (kmax of Omepra-
zole), respectively. They were scanned in the wavelength range
of 200–400 nm and the overlain spectrum was obtained (Fig 3).
2.2.3. Preparation of calibration curve
For each drug, appropriate aliquots were pipetted out from each
standard stock solution into a series of 10 ml volumetric ﬂasks.
The volumewasmade up to themarkwithmethanol and double
distilled water (50:50) to get a set of solutions having a concen-
tration range of 5–30 lg/ml for bothDrotaverine hydrochloride
and Omeprazole. Triplicate dilutions of each concentration of
each drugwere prepared separately. The preparedworking solu-
tions of Drotaverine hydrochloride and Omeprazole were
scanned at 226.8 nm and 269.4 nm, respectively. The respective
absorbances were recorded and absorbances were plotted
against the concentrations to obtain their respective calibration
curves. The absorptivity coefﬁcients of each drug at both wave-
lengths were determined. The concentration of two drugs in the
mixture was calculated using equationsTable 1 Optical and regression characteristic parameters for Drota
Parameters Absorptivity at 226.8 nm
Drotaverine hydrochlorid
Beer’s law limit (mg/ml) 5–30
Molar absorptivity 3.1 X 103
Sandell’s sensitivity 2817.36
Correlation coeﬃcient (r2) 0.9996
Relative standard deviation (RSD or%CV) 0.147
LOD (lg/ml) 0.935
LOQ (lg/ml) 1.173
Regression equation 0.0386
Mean ax1 = 413.65
Standard deviation (SD) 0.0641CDRO ¼ A2 ay1A1 ay2=ax2 ay1 ax1ay2 ð1Þ
COME ¼ A1 ax2A2 ax2=ax2ay1 ax1ay2 ð2Þ
where, A1 and A2 are absorbance of mixture at 226.8 nm and
269.4 nm; ax1 and ax2, absorptivities of Drotaverine hydro-
chloride at 226.8 nm and 269.4, respectively; ay1 and ay2
absorptivities of Omeprazole at 226.8 nm and 269.4 nm,
respectively. CDRO and COME are concentration of Drotaver-
ine hydrochloride and Omeprazole in mixture. The absorptiv-
ities reported are the mean of six independent determinations
(Table 1). Before analyzing the selected tablet formulations
the method was validated by analyzing the physical admixtures
of Drotaverine hydrochloride and Omeprazole in the ratio of
each component as in the formulation in consideration.
2.2.4. Preparation of sample solution
Contents of twenty tablets were weighed accurately and pow-
dered. Powder equivalent to 40 mg of Drotaverine hydrochlo-
ride and 10 mg of Omeprazole was weighed. The tablets were
triturated with the help of mortar and pestle and made into
a ﬁne powder and the residue equivalent to the average weight
of a tablet was dissolved in a mixture of methanol and double
distilled water (50:50) and sonicated for 10 min in the sonica-
tor. The solution was ﬁltered through Whatman ﬁlter paper
No. 41 into a 100 mL volumetric ﬂask. Filter paper was
washed with methanol, adding washings to the volumetric
ﬂask and the volume was made up to the mark with methanol
to get the sample stock solution which was further diluted with
0.1 N HCl to get the ﬁnal concentration of solution (Drotaver-
ine hydrochloride 5 lg mL1 and Omeprazole 10 lg mL1) in
the linearity range.
2.3. Reverse phase high performance liquid chromatographic
method
A reverse phase high performance liquid chromatographic
method was developed for the simultaneous estimation of Dro-
taverine hydrochloride and Omeprazole in tablet formulation.
All the chemical and reagents used were of HPLC grade and
purchased from Spectrochem, Mumbai, India.
2.3.1. Instrument
The HPLC system is equipped with an LC-10 AT VP solvent-
delivery system with a universal loop injector (Rheodyne 7725
i) of an injection capacity of 20 lL. Detector consists of
photodiode array detector SPD-10 AVP UV–Visible detector.verine hydrochloride and Omeprazole.
Absorptivity at 269.4 nm
e Omeprazole Drotaverine hydrochloride Omeprazole
5–30 5–30 5–30
1.6 X 103 2.8 X 103 1.1 X 103
2014.24 1941.71 1039.22
0.9999 0.9984 0.9991
0.068 0.181 0.027
0.746 0.136 0.0297
0.384 0.247 0.0413
0.0218 0.0147 0.0390
ay1 = 486.17 ax2 = 366.18 ay2 = 336.96
0.0318 0.0864 0.0548
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(5 lm · 25 cm · 4.6 mm i.d) under reversed phase partition
chromatographic conditions. The equipment was controlled
by a PC workstation. The work was carried out in an air-con-
ditioned room maintained at temperature 25 ± 2 C. Chro-
matograms were recorded using CLASS-VP software
(Shimadzu, Kyoto, Japan).
2.3.2. Chromatographic conditions
The optimal composition of the mobile phase was determined
to be potassium dihydrogen phosphate buffer pH 5.0: Acetoni-
trile: Triethylamine (60:40:0.5, v/v). The ﬂow rate was set to
1 mL min1 and UV detection was carried out at 260 nm. Cip-
roﬂoxacin was used as an internal standard. The mobile phase
was ﬁltered through nylon 0.22 lm membrane ﬁlter and was
degassed before use.
Stock solution was prepared by dissolving Drotaverine
hydrochloride and Omeprazole (10 mg each) that were
weighed accurately and separately transferred into 100 mL vol-
umetric ﬂasks. Both drugs were dissolved in 25 methanol to
prepare standard stock solutions. After the immediate dissolu-
tion, the volume was made up to the mark with mobile phase.
These standard stock solutions were observed to contain
100 lg ml1 of Drotaverine hydrochloride and Omeprazole.
Ciproﬂoxacin (internal standard) was taken in a separate
10 mL volumetric ﬂask and dissolved in methanol. Then the
volume was made up to the mark with the same solvent.
Appropriate volume from this solution was further diluted to
get appropriate concentration levels according to the require-
ment. From the above stock solutions, dilutions were made
in the concentration range of 5–30 lg mL–1 of Drotaverine
hydrochloride and Omeprazole, respectively and each concen-
tration contains 5 lg mL–1 of Ciproﬂoxacin (internal stan-
dard). A volume of 20 lL of each sample was injected into
column.
2.3.3. Analysis of marketed formulation
Twenty tablets were weighed the average weight was deter-
mined and these were powdered. Sample solution was then
prepared by dissolving the powdered tablets equivalent to
40 mg of Drotaverine hydrochloride and 10 mg of Omeprazole
in a 100 mL of volumetric ﬂask. Then the drugs were dissolved
by using 25 mL methanol and the volume was made up to the
mark with methanol. 5 mL of this solution was further diluted
to 25 mL with the same solvent. With the optimized chromato-
graphic conditions, a steady baseline was recorded, the mixed
standard solution was injected and the chromatogram was re-
corded. Both compounds were identiﬁed by comparison of
retention times obtained from sample and standard solutions.Table 2 Analysis of data of tablet formulations.
S.No Parameters UV spectrophotometry HPLC
Drotaverine hydrochloride Omeprazole Drotaverin
1 Label claim 40 10 40
2 Drug content* 99.48 99.59 100.08
3 ±S.D 0.26 0.48 0.16
4 % COV 0.11 0.35 0.60
S.D. is standard deviation.
* Value for Drug content (%) are the mean of ﬁve estimations.The work was performed in an air-conditioned room main-
tained at 25 ± 2 C. The retention time of Drotaverine hydro-
chloride and Omeprazole was found to be 2.71 and 3.87 min,
respectively. The results are reported in Table 2. The resolu-
tion, number of theoretical plates, retention time and peak
asymmetry were calculated for the working standard solutions
and is as shown in Table 3. The values obtained demonstrated
the suitability of the system for the analysis of these drugs in
combination. The typical chromatogram of standard solution
is as shown in Fig. 4.
2.4. TLC Densitometric method
2.4.1. Chromatographic conditions
Drotaverine hydrochloride and Omeprazole were simulta-
neously determined by HPTLC in pharmaceutical formula-
tions. The drugs were separated on silica gel 60 F254 plates
using a suitable combination of solvents as mobile phase.
The validation parameters, tested in accordance with the
requirements of ICH guidelines, prove the suitability of meth-
ods. The samples were spotted in the form of bands of a width
of 4 mm with space between bands of 6 mm, with a 100 lL
sample syringe (Hamilton, Bonaduz, Switzerland) on pre-
coated silica gel 60 F254 aluminum HPTLC plates
(20 cm · 10 cm) with automatic sample applicator LINOMAT
V. The plates were prewashed with methanol and activated at
130 C for 5 min, prior to chromatography. Chromatographic
separation studies were carried out on the stock solution of
Drotaverine hydrochloride and Omeprazole. Initially on the
plates 6 lL of stock solution was applied as a band of 8 mm
of width. Plates were developed by linear ascending develop-
ment using neat solvents like toluene, hexane, methanol, chlo-
roform, dichloromethane, ethyl acetate, acetone, acetonitrile,
etc., without chamber saturation. Based on the results of these
initial chromatograms binary and ternary mixtures of solvents
were tried to achieve optimum resolution between Drotaverine
hydrochloride and Omeprazole respectively. After several tri-
als, mixture of Glacial acetic acid: Cyclohexane: Methanol:
(80:15:5v/v/v) was chosen as the mobile phase for analysis.
Other chromatographic conditions like chamber saturation
time, run length, sample application rate and volume, sample
application positions, distance between tracks, detection wave-
length, were optimized to give reproducible RF values, better
resolution, and symmetrical peak shape for the two drugs.
The optimized chamber saturation time for the mobile phase
was 30 min at room temperature (28 ± 2 C). The length of
the chromatogram run was approximately 60 mm. The spot
appeared more compact and peak shape more symmetrical
when the TLC plates were pre-treated with methanol andHPTLC
e hydrochloride Omeprazole Drotaverine hydrochloride Omeprazole
10 40 10
101.06 99.86 98.96
0.03 0.14 0.85
0.25 0.19 0.43
Table 3 System suitability parameters of HPLC method.
Parameters Drotaverine hydrochloride Omeprazole
Tailing factor 2.63 4.97
Theoretical plates 5249 7491
Resolution factor 3.13 4.95
Asymmetry factor 1.44 1.58
Height 43721 51227
Area 237236 353241
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were obtained when the chamber saturation time was optimized
at 20 min at room temperature. After development the plates
were dried in current of air by an air dryer. Detection of spot
was then performed at 295 nm with a CAMAG TLC Scanner
3 in the absorbance mode operated by winCATS software.
The source of radiation was a deuterium lamp. Slit dimensions
were 5 mm · 0.1 mm and the scanning speed 20 mm/s.
2.4.2. Preparation of standard and sample solutions
Standard stock solution containing 400 lg/ml of Drotaverine
hydrochloride and 100 lg/ml of Omeprazole was prepared in
methanol. Linearity was performed by applying six times the
stock solution to give concentrations of 100–600 and 200–
600 ng/spot of Drotaverine hydrochloride and Omeprazole,
respectively. Calibration curve was established by plotting
peak area on ordinate and corresponding concentration on ab-
scissa. The developed chromatograms were evaluated by scan-
ning in densitometry mode at 295 nm. The amount of
Drotaverine hydrochloride and Omeprazole present per tablet
was calculated by comparing peak area of sample with that of
standard (Sethi, 1996).
Twenty tablets were accurately weighed, and their average
weight was determined. Powder equivalent to 40 mg of Drota-
verine hydrochloride and 10 mg of Omeprazole was dissolvedFigure 4 Representative HPLC chromatogram oin methanol, sonicated for 20 min; solution was ﬁltered and di-
luted to 100 ml with methanol. The solution was applied on the
plate to give 100–600 ng/spot of Drotaverine hydrochloride
and 200–600 ng/spot of Omeprazole, respectively. The results
of assay are summarized in (Table 5). The method was vali-
dated as per the various parameters given in ICH guidelines
(ICH guidelines, 1996). The linearity was studied in the con-
centration range of 100–600 ng/spot of Drotaverine hydro-
chloride and 200–600 ng/spot of Omeprazole, respectively.
Precision of the method is expressed in terms of % RSD.
Recovery studies were performed by the standard addition
method at 80%, 100% and 120% levels, to the pre-analyzed
samples and contents were reanalyzed, using the proposed
method (Table 4). Ruggedness of the proposed method was
determined by performing assays by two different analysts,
using similar operational and environmental conditions. The
developed method was validated in terms of linearity, accu-
racy, limit of detection, limit of quantiﬁcation, intra-day and
inter-day precision and repeatability of measurement as well
as repeatability of sample application (ICH guidelines, 1996).
The analysis was repeated in triplicate. The content of the drug
was calculated from the peak areas recorded.
3. Results and discussion
Both, UV spectrophotometric, HPLC and HPTLC methods
were found to be for routine simultaneous estimation of Dro-
taverine hydrochloride and Omeprazole, in tablet dosage
forms. The proposed method for simultaneous estimation of
Drotaverine hydrochloride and Omeprazole utilizes the spec-
trum mode of analysis of spectrophotometer. The method uti-
lizes 226.8 nm and 269.4 nm as an analytical wavelength for
the estimation of Drotaverine hydrochloride and Omeprazole.
The method employing simultaneous equation is a very simple
method and can be employed for a routine analysis of Drota-
verine hydrochloride and Omeprazole. Once the absorptivityf Drotaverine hydrochloride and Omeprazole.
Table 5 Summary of repeatability, precision and ruggedness.
Parameter UV-Spectrophotometry HPLC HPTLC
DRO OME DRO OME DRO OME
Repeatability 1.83 0.762 0.88 0.64 0.96 0.38
Precision intra-day 1.07 0.13 0.29 0.43 0.8 0.49
Inter-day 0.29 0.14 0.56 1.55 1 0.72
Ruggedness 0.68 0.52 0.37 0.87 0.34 0.65
RF – – – – 0.38 0.56
Linearity (ng per band) – – – – 100–600 200–600
Linearity detection (ng/spot) – – – – 68 82
Limit of quantiﬁcation (ng/spot) – – – – 294 397
n is the number of repetitions; DRO-Drotaverine hydrochloride,OME-Omeprazole.
Table 4 Recovery studies.
UV-Spectrophotometry HPLC HPTLC
Excess drug *Recovery % COV Excess drug *Recovery % COV Excess drug *Recovery % COV
Drotaverine hydrochloride
80 100.09 0.53 80 99.82 0.94 80 100.28 0.09
100 100.06 0.38 100 99.92 0.01 100 100.09 0.7
120 100.27 0.17 120 100.26 0.97 120 101.11 0.21
Omeprazole
80 99.91 0.28 80 99.86 0.28 80 99.98 0.15
100 99.98 0.49 100 99.52 0.31 100 100.11 0.39
120 98.83 1.17 120 100.16 0.63 120 99.9 0.68
*Average of six estimations.
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as it would only require the determination of absorbances of
the sample solution at two selected wavelengths and few simple
calculations. For UV spectrophotometric method, linearity
was obtained in the concentration range of 5–30 lg mL1,
for both the drugs; with regression 0.9996 and 0.9999, intercept
0.0386 and 0.0218 and slope 0.0854 and 0.0292 for Drota-
verine hydrochloride and Omeprazole, respectively. Recovery
was in the range of 99 –101%; the values of standard deviation
and% R.S.D. were found to be <2%; shows the high preci-
sion of the method (Table 4). The low values of these statistical
parameters validated the method. LOD and LOQ were found
to be 0.935 and 1.173 for Drotaverine hydrochloride and 0.746
and 0.384 for Omeprazole, respectively. Interday and intraday
precision studies showed % RSD values <1% that signify the
precision of the method.
In HPLC method, an adequate separation of eluted com-
pounds was optimized. Mobile phase and ﬂow rate selection
were based on peak parameters (height, tailing, theoretical
plates, capacity factor), run time etc. Several aliquots of stan-
dard solutions of Drotaverine hydrochloride and Omeprazole
were taken in different 10 ml volumetric ﬂasks and diluted up
to the mark with a mobile phase such that the ﬁnal concentra-
tion of Drotaverine hydrochloride and Omeprazole is 5–
30 lg mL1, respectively. The system with potassium dihydro-
gen phosphate buffer pH 5.0: Acetonitrile: Triethylamine
(60:40:0.5, v/v) with 1 mL min1 ﬂow rate is quite robust.
The optimum wavelength for detection was 260 nm at which
better detector response for drugs was obtained. The average
retention times for Drotaverine hydrochloride and Omepra-
zole were found to be 2.71 and 3.87 min, respectively. The peakshapes of both the drugs were symmetrical and the asymmetry
factor was lesser than 2.0. The proposed method was validated
as per the standard analytical procedures. Each of the samples
was repeated 6 times and the same retention time was observed
in all the cases. Precision of proposed HPLC method was
found to be 0.0178 (RSD) for Drotaverine hydrochloride
and 0.0048 for Omeprazole that indicate good precision of
the samples analyzed. The correlation coefﬁcient ‘r’ values
(n= 6) for both Drotaverine hydrochloride and Omeprazole
were P0.999. Accuracy of the method was calculated by
recovery studies (n= 3) at three levels. The method was found
to be accurate and precise as indicated by results of recovery
studies and % RSD not more than 2%. LOD and LOQ for
Omeprazole were found to be 0.63 and 0.98 lg/ml respectively
and for Drotaverine were 1.41 and 1.79 lg/ml, respectively.
The mean recoveries obtained for Drotaverine hydrochloride
and Omeprazole were 99.36% and 101.03%, respectively.
In HPTLC method, Chromatographic separation of the
drugs was performed on aluminum plates precoated with silica
gel 60 F254, with Glacial acetic acid: Cyclohexane: Methanol:
(80:15:5v/v/v) as mobile phase. Chromatographic evaluation
of the separated zones was performed at 295 nm. The linear
regression data for the calibration plots showed good linear
relationship with r2 0.9997 and 0.9984 in the concentration
range of 100–600 ng/spot and 200–600 ng/spot for Drotaverine
hydrochloride and Omeprazole, respectively were applied, in
duplicate, to a TLC plate, and after development peak height
and peak area data and drug concentration data were treated
by linear least-squares regression to determine linearity. The
accuracy and reliability of the method was assessed by an eval-
uation of linearity (100–600 ng/spot for Drotaverine hydro-
Table 6 Robustness of the HPTLC method.
Parameter ±S.D. of peak
area (n= 6)
% COV
(n= 6)
Mobile phase composition 48.62 0.82
Time from application to
development (±10 min)
36.83 0.56
Time from development to
scanning (±10 min)
31.70 0.64
Activation of TLC plates 33.64 0.72
n-number of determinations.
Development and validation of new analytical methods S403chloride, and 200–600 ng/spot for Omeprazole), precision (in-
tra-day RSD 0.48–0.82% and inter-day RSD 1.16–1.64% for
Drotaverine hydrochloride, and intra-day RSD 0.48–0.63%
and inter-day RSD 0.18–0.53% for Omeprazole), accuracy
(99.61 ± 0.14% for Drotaverine hydrochloride and
99.08 ± 0.31% for Omeprazole), and speciﬁcity, in accordance
with ICH guidelines (Table 5). The LOD and LOQ were deter-
mined from the slope of the lowest part of the calibration plot.
The LOD and LOQ were 36 ± 0.16 and 57 ± 0.25 ng, respec-
tively, for Drotaverine hydrochloride and 18 ± 1.01 and
72.0 ± 0.26 ng, respectively, for Omeprazole, which indicate
the sensitivity of the method is adequate. Rf Spots at Rf
0.38 ± 0.82 for Drotaverine hydrochloride and 0.56 ± 0.12
for Omeprazole were observed in the chromatogram obtained
from Drotaverine hydrochloride and Omeprazole extracted
from tablets (Table 6). There was no interference from excipi-
ents commonly present in the tablets. The Drotaverine hydro-
chloride and Omeprazole content were found to be 100.0–
100.53% and 99.02–99.89%, respectively, of the label claim.
The low values of% RSD are indicative of the high repeatabil-
ity of the method. The low values of% RSD obtained after
introducing small changes in mobile phase composition and
volume were indicative of the robustness of the method. There
was no signiﬁcant variation of the slopes of the calibration
plots.
4. Conclusion
The developed UV Spectrophotometric method, RP-HPLC
and HPTLC technique is precise, speciﬁc, and accurate. The
method was simple and had a short runtime of 10 min, which
makes the method rapid. The results of the study indicate that
the proposed HPLC method was simple, precise, highly accu-
rate, speciﬁc and less time consuming. Statistical analysis
proves that the method is repeatable and selective for the anal-
ysis of Drotaverine hydrochloride and Omeprazole as bulk
drug and in pharmaceutical formulation without any interfer-
ence from the excipients. The method can be used to determine
the purity of the drug available from various sources by detect-
ing the related impurities. The results of the recovery studies
performed show the high degree of accuracy of the proposed
methods.Acknowledgements
We are grateful to Prof. D.V. Kohli and Prof. Abhay Kumar
Singhai Department of Pharmaceutical Sciences Dr. H.S.
Gaur, Sagar University Sagar (M.P) India, and Head, Schoolof Pharmacy, Devi Ahilya Vishwavidyalaya, Indore (M.P)
452001 India for the facility given and valuable suggestion.
Reference
Abdellatef, H.E., Ayad, M.M., Soliman, S.M., Youssef, N.F., 2007.
Spectrochim. Acta, Part A 66, 1147–1151.
Agbaba, D., Novovic, D., Karaljikovic, K., Maronqovic, V., 2004. J.
Planar Chromatogr.–Mod. TLC 17, 169–172.
Ayad, M.M., Youssef, N.F., Abdellatif, H.E., Soliman, S.M., 2006.
Chem. Pharm. Bull. 54, 6807.
Berzas, J.J., Castanda, G., 2005. Anal. Chem. Acta 533, 127–132.
Bolaji, O., Onyeji, C., Ogungbamila, F., Ogunbona, F., 1993. J.
Chromatogr., B 93, 622.
Dahivelkar, P.P., Mahajan, V.K., Bari, S.B., Shirkhedkar, A.A.,
Fursule, R.A., Surana, S.J., 2007. Indian J. Pharm. Sci. 69, 812–
814.
Davidson, A.G., Beckett, A.H., Stenlake, J.B., 2001. Practical Phar-
maceutical Chemistry, fourth ed. CBS Publishers and Distributor,
New Delhi.
Dubuc, M.C., Hamel, C., Caubet, M.S., Brazier, J.L., 2001. J. Liq.
Chromatogr. Relat. Technol. 24, 1161–1169.
El-Sherif, Z.A., Mohamed, A.O., El-Bardicy, M.G., El-Tarras, M.F.,
2006. Chem. Pharm. Bull. 54, 6814.
Gregory, W.S., John, D.S., James, H.A., Zheng, Z., 2001. J. Pharm.
Biomed. Anal. 25, 357–362.
ICH, 1996, Q2B Validation of analytical procedure: methodology. in:
International Conference on Harmonization, Geneva; March.
Kange, Z., Huijuan, J., Wei, L., 2006. J. Chromatogr., B 837, 112–116.
Kothapalli, L.P., Dewoolkar, V.C., Banerjee, A.G., Thomas, A.B.,
Nanda, R.K., Deshpande, A.D., Hurne, V.A., 2010. Int. J. Chem.
Tech. Res. 2 (1), 493–498.
Lakshmi, S., Venkatesan, M., 2003. Ind. Drugs 40, 589–592.
Lalla, J.K., Shah, M.U., Jain, M.B., Sharma, A.H., 1993. J. Pharm.
Biomed. Anal. 11, 385.
Metwally, F.H., 2008. Spectrochim. Acta, Part A 69, 343–349.
Metwally, F.H., Abdelkawy, M., Naguib, I.A., 2006. J. AOAC Int. 89,
78–87.
Murakami, F.S., Cruz, A.P., Pereira, R.N., Valente, B.R., Silva,
M.A.S., 2007. J. Liq. Chromatogr. Relat. Technol. 30, 113–121.
Oneil, M.J., Smith, A., Heckelman, P.E., 2001. In: The Merck Index,
vol. 13. Merck Whitehouse Station, New Jersey, p. 3489.
Panigrahi, D., Sharma, R., 2008. Acta Chromatogr. 20, 439.
Patel, B., Patel, M., Patel, J., 2007. J. Liq. Chromatogr. Relat.
Technol. 30, 1749–1762.
Petsalo, A., Turpeinen, M., Pelkonen, O., Tolonen, A., 2008. J.
Chromatogr., A 1215, 107–115.
Raval, P.B., Puranik, M., Wadher, S.J., Yeole, P.G., 2008. Indian J.
Pharm. Sci. 70, 386–390.
Sethi, P.D., 1996. High Performance Thin Layer Chromatography
Quantitative Analysis of Pharmaceutical Formulations, ﬁrst ed.
CBS Publishers and Distributors.
Stenhoff, H., Blomqvist, A., Lagerstrom, P.O., 1999. J. Chromatogr.,
B 734, 191–201.
Subramanian, L.S., kumar, V.A., 2007. Indian J. Pharm. Sci. 69, 674–
676.
Sweetman, S.C. (Ed.), 2002. Martindale: The Complete Drug Refer-
ence. Pharmaceutical Press, London.
Topagi, K.S., Jeswani, R.M., Sinha, P.K., Damle, M.C., 2010. Asian J.
Pharmacol. Clin. Res. 3 (1), 20–24.
Tripathi, K.D., 2008. Essentials of Medical Pharmacology, sixth ed.
Jaypee Brothers Medical publishers (P) ltd, New Delhi, pp 631–
633.
Yuch, K., Wai, P.C., Huey, Y.T., Jia, W.W., 2001. J. Pharm. Biomed.
Anal. 24, 715–719.
Ziyatdinova, G.K., Samigullin, A.I., Budnikov, G.K., 2007. J. Anal.
Chem. 62, 773–776.
